Lilly’s new diabetic drug approved and ready to go to market,

Mounjaro is a new injection for type 2 diabetes that lowers blood sugar and can help patients lose weight. Clinical trials of Mounjaro show it to be more effective than other treatments.

ELi Lilly’s Mounjaro, known by the generic name Tirzepatide, will compete with other injectable drugs like Trulicity and Ozempic. Current medications target the glucagon-like peptide-1 hormone that helps control blood sugar. Mounjaro also targets the glucose-dependent insulinotropic polypeptide hormone and is the first drug to target both hormones.

In addition to effectively controlling blood sugar levels, test subjects also lost weight while taking Mounjaro either with or without insulin, showing promise as a means of helping combat obesity.

Side effects of taking Mounjaro may include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain. Mounjaro is not indicated for use in patients with type 1 diabetes. “Specialty Rx is excited by these new developments that may help improve overall health and quality of life for our patients,” stated Ankur Dave, Pharm D. Compliance Officer.